中国合理用药探索2025，Vol.22Issue(7)：36-42,7.DOI:10.3969/j.issn.2096-3327.2025.07.003
安罗替尼联合帕博利珠单抗对晚期子宫内膜癌患者肿瘤标志物、微小核糖核酸表达的影响
Effects of Anlotinib Combined with Pembrolizumab on Tumor Markers and MicroRNA Expression in Patients with Advanced Endometrial Cancer
摘要
Abstract
Objective:To explore the effects of anlotinib combined with pembrolizumab on tumor markers and microRNA(miRNA)expression in patients with advanced endometrial cancer.Methods:A total of 87 patients with advanced endometrial cancer admitted to a hospital from January 2021 to January 2023 were selected and divided into Group A,Group B and Group C by random number table method,with 29 patients in each group.Group A was treated with anlotinib hydrochloride capsules,Group B with pembrolizumab injection,and Group C with anlotinib hydrochloride capsules combined with pembrolizumab injection.Tumor markers[carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199),osteopontin(OPN)],humoral immune indicators[immunoglobulin(Ig)M,IgG,IgA],miRNA(miR-125b,miR-29a,miR-425-5p),functional assessment of cancer therapy(FACT-G)scores,clinical efficacy and adverse reactions were compared among the three groups.Results:After treatment,serum levels of CA125,CA199,OPN and relative expression of miR-425-5p were decreased in three groups(P<0.05),with lower levels in Group C than in Group A and Group B(P<0.05).Serum levels of IgG,IgM and IgA were decreased in three groups(P<0.05),but Group C showed higher levels than Group A and Group B(P<0.05).Relative expression of miR-125b and miR-29a,the scores of all FACT-G dimensions and the total score were increased in three groups(P<0.05),with higher levels/scores in Group C than in Group A and Group B(P<0.05).The objective response rate in Group C was higher than that in Group A and Group B(P<0.05).There were no statistically significant differences in the incidences of fatigue,hypertension,diarrhea,hand-foot syndrome and the total incidence among the three groups during treatment(P>0.05).Conclusion:Anlotinib combined with pembrolizumab shows good clinical efficacy in treating patients with advanced endometrial cancer.It can effectively reduce tumor marker levels,improve immune function and miRNA expression,enhance quality of life,and does not increase the risk of adverse reactions.关键词
安罗替尼/帕博利珠单抗/晚期/子宫内膜癌/肿瘤标志物/免疫功能Key words
anlotinib/pembrolizumab/advanced/endometrial cancer/tumor marker/immune function分类
医药卫生引用本文复制引用
张银珂,刘军华,高立娟,陈晓亮..安罗替尼联合帕博利珠单抗对晚期子宫内膜癌患者肿瘤标志物、微小核糖核酸表达的影响[J].中国合理用药探索,2025,22(7):36-42,7.基金项目
中国平煤神马能源化工集团有限责任公司科研项目(4104022021180701) （4104022021180701）
